Also known as: Otezla (brand)
Apremilast is an oral PDE4 inhibitor used in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. It modulates inflammatory mediators to reduce symptoms. Mediocon Inc supplies pharmaceutical-grade Apremilast meeting IP/BP/EP/USP standards for pharma manufacturers.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Apremilast (CAS 608141-41-9) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Apremilast is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance